TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 89nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 210nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 380nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 390nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 580nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 580nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 880nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 3.88E+3nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair